Marta Całus, Konrad Bagiński, Małgorzata Duzinkiewicz, Julia Nowowiejska, A. Baran, I. Flisiak
{"title":"免疫抑制患者红斑狼疮的诊断难题","authors":"Marta Całus, Konrad Bagiński, Małgorzata Duzinkiewicz, Julia Nowowiejska, A. Baran, I. Flisiak","doi":"10.5603/fd.96995","DOIUrl":null,"url":null,"abstract":"Introduction: Erysipelas is an acute inflammatory condition of the skin and subcutaneous tissue caused by Streptococci . The lesions usually affect the lower limbs or face unilaterally and are characterized by erythema, oedema and pain. By the definition, the disease is accompanied by high fever. On the laboratory investigations, elevated C-reactive protein and leukocytosis are observed. However, in immunocompromised patients, the diagnosis might be unclear. Case description: This study presents cases of three patients admitted to the department of dermatology with erysipelas: a 51-year-old woman with rheumatoid arthritis treated with tocilizumab, methotrexate and methylprednisolone, a 51-year-old woman with systemic lupus erythematosus treated with prednisone, and a 75-year-old woman with rheumatoid arthritis treated with methotrexate. Clinical pictures shared common symptoms in all cases: oedema, erythema and pain in one of the limbs. However, none of the patients had a fever on admission. On laboratory tests, in two cases, there was no significant increase in inflammatory markers. The treatment with intravenous antibiotics and low-molecular heparin resulted in good clinical improvement. Conclusions: Chronic immunosuppressive treatment acting due to inhibition of pro-inflammatory cytokines reduced patients’ immune response, which resulted in the absence of fever and no significant increase in the inflammatory parameters. Presented cases show some peculiarities of erysipelas in the distinct group of immunosuppressed patients and draw attention to unusual manifestations. Nowadays, there are more and more patients treated with biological agents for different diseases, including dermatoses. Hence, the number of atypical erysipelas cases may rise.","PeriodicalId":507706,"journal":{"name":"Forum Dermatologicum","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Difficulties in the diagnosis of erysipelas in immunosuppressed patients\",\"authors\":\"Marta Całus, Konrad Bagiński, Małgorzata Duzinkiewicz, Julia Nowowiejska, A. Baran, I. Flisiak\",\"doi\":\"10.5603/fd.96995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Erysipelas is an acute inflammatory condition of the skin and subcutaneous tissue caused by Streptococci . The lesions usually affect the lower limbs or face unilaterally and are characterized by erythema, oedema and pain. By the definition, the disease is accompanied by high fever. On the laboratory investigations, elevated C-reactive protein and leukocytosis are observed. However, in immunocompromised patients, the diagnosis might be unclear. Case description: This study presents cases of three patients admitted to the department of dermatology with erysipelas: a 51-year-old woman with rheumatoid arthritis treated with tocilizumab, methotrexate and methylprednisolone, a 51-year-old woman with systemic lupus erythematosus treated with prednisone, and a 75-year-old woman with rheumatoid arthritis treated with methotrexate. Clinical pictures shared common symptoms in all cases: oedema, erythema and pain in one of the limbs. However, none of the patients had a fever on admission. On laboratory tests, in two cases, there was no significant increase in inflammatory markers. The treatment with intravenous antibiotics and low-molecular heparin resulted in good clinical improvement. Conclusions: Chronic immunosuppressive treatment acting due to inhibition of pro-inflammatory cytokines reduced patients’ immune response, which resulted in the absence of fever and no significant increase in the inflammatory parameters. Presented cases show some peculiarities of erysipelas in the distinct group of immunosuppressed patients and draw attention to unusual manifestations. Nowadays, there are more and more patients treated with biological agents for different diseases, including dermatoses. Hence, the number of atypical erysipelas cases may rise.\",\"PeriodicalId\":507706,\"journal\":{\"name\":\"Forum Dermatologicum\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Forum Dermatologicum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/fd.96995\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum Dermatologicum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/fd.96995","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介红斑狼疮是由链球菌引起的皮肤和皮下组织的急性炎症。皮损通常发生在单侧下肢或面部,以红斑、水肿和疼痛为特征。根据定义,该病伴有高烧。在实验室检查中,可观察到 C 反应蛋白升高和白细胞增多。然而,对于免疫力低下的患者,诊断可能并不明确。病例描述本研究介绍了皮肤科收治的三名红斑狼疮患者的病例:一名 51 岁的类风湿性关节炎女性患者,使用妥昔单抗、甲氨蝶呤和甲泼尼龙治疗;一名 51 岁的系统性红斑狼疮女性患者,使用泼尼松治疗;一名 75 岁的类风湿性关节炎女性患者,使用甲氨蝶呤治疗。所有病例都有共同的临床症状:水肿、红斑和一侧肢体疼痛。然而,所有患者在入院时都没有发烧。在实验室检查中,有两个病例的炎症指标没有明显增加。经静脉注射抗生素和低分子肝素治疗后,临床症状得到了很好的改善。结论抑制促炎细胞因子的慢性免疫抑制治疗可减轻患者的免疫反应,从而使患者不发烧,炎症指标也没有明显增加。上述病例显示了红斑狼疮在免疫抑制患者这一特殊群体中的一些特殊性,并引起了人们对不寻常表现的关注。如今,越来越多的患者因各种疾病(包括皮肤病)而接受生物制剂治疗。因此,非典型红斑狼疮病例的数量可能会增加。
Difficulties in the diagnosis of erysipelas in immunosuppressed patients
Introduction: Erysipelas is an acute inflammatory condition of the skin and subcutaneous tissue caused by Streptococci . The lesions usually affect the lower limbs or face unilaterally and are characterized by erythema, oedema and pain. By the definition, the disease is accompanied by high fever. On the laboratory investigations, elevated C-reactive protein and leukocytosis are observed. However, in immunocompromised patients, the diagnosis might be unclear. Case description: This study presents cases of three patients admitted to the department of dermatology with erysipelas: a 51-year-old woman with rheumatoid arthritis treated with tocilizumab, methotrexate and methylprednisolone, a 51-year-old woman with systemic lupus erythematosus treated with prednisone, and a 75-year-old woman with rheumatoid arthritis treated with methotrexate. Clinical pictures shared common symptoms in all cases: oedema, erythema and pain in one of the limbs. However, none of the patients had a fever on admission. On laboratory tests, in two cases, there was no significant increase in inflammatory markers. The treatment with intravenous antibiotics and low-molecular heparin resulted in good clinical improvement. Conclusions: Chronic immunosuppressive treatment acting due to inhibition of pro-inflammatory cytokines reduced patients’ immune response, which resulted in the absence of fever and no significant increase in the inflammatory parameters. Presented cases show some peculiarities of erysipelas in the distinct group of immunosuppressed patients and draw attention to unusual manifestations. Nowadays, there are more and more patients treated with biological agents for different diseases, including dermatoses. Hence, the number of atypical erysipelas cases may rise.